Cite
MLA Citation
D. Lüftner et al.. “Neratinib as extended adjuvant therapy in patients with HER2-positive/HR-positive early breast cancer: German HTA-driven analyses from the ExteNET study.” Breast, vol. 56, n.d., pp. S17–. http://access.bl.uk/ark:/81055/vdc_100123996175.0x000030